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We report a case with pulmonary veno-occlusive disease (PVOD) associated with 
systemic sclerosis which exhibits strong resistance to pulmonary vasodilator.  
A 55-year-old female with severe pulmonary hypertension was admitted to our hospital to 
be introduced epoprostenol infusion therapy. She was diagnosed as pulmonary arterial 
hypertension (PAH) associated with systemic sclerosis at the age of 51. Several aggressive 
treatments with pulmonary vasodilators, including oral prostaglandin, endothelin receptor 
antagonists, and phosphodiesterase 5 inhibitors, failed to improve her symptoms. We 
introduced continuous intravenous epoprostenol therapy from 2 μg/kg/min for her. However, 
pulmonary edema appeared and worsened dose dependent manner. We made a diagnosis 
as PVOD clinically at that time. Thereafter, pulmonary edema gradually disappeared in 
consistent with the reduction of the dose of epoprostenol infusion. She died of renal failure 
and infection 4 months after the introduction of epoprostenol infusion therapy. A histological 
examination revealed severe stenosis and occlusions of pulmonary veins as well as 
pulmonary arteries over a wide area. We suggest that prevalence of veno-occlusive type of 
disease could be one of the major mechanisms of less responsive or even refractory to 










Recent advances regarding the treatment for pulmonary hypertension, especially, for 
pulmonary arterial hypertension (PAH) have improved the prognosis of patients with PAH 
[1, 2]. Several reports have described that connective tissue diseases such as systemic 
sclerosis and systemic lupus erythematosus could be complicated by severe PAH which 
worsens their prognosis [3, 4]. Pulmonary hypertension associated with connective tissue 
disease has been categorized into PAH. Pulmonary veno-occlusive disease (PVOD) has 
been described as a relatively rare cause of pulmonary hypertension that affects 
predominantly post-capillary pulmonary vessels. A major concern with PVOD is the poor 
responsiveness to available pulmonary vasodilator, especially, the risk of pulmonary 
edema with continuous intravenous epoprostenol therapy [5, 6]. We recently experienced a 
case with PVOD associated with systemic sclerosis which exhibited strong resistance to 
pulmonary vasodilator, including continuous intravenous epoprostenol therapy.  
 
Case report 
A 55-year-old female admitted to our hospital for the introduction of epoprostenol infusion 
therapy. She was diagnosed as systemic sclerosis at the age of 39. And the initial diagnosis 
of her pulmonary hypertension was made when she was 51 years old. She had been 
treated with beraprost since then. Thereafter, her symptoms of dyspnea gradually 
worsened associated with the increase of pulmonary artery pressure in spite of the 
introduction of sildenafil, ambrisentan and home oxygen therapy during four years of 
clinical course. Physical examination at the admission revealed a heart rate of 80 bpm, a 
blood pressure of 90/52 mmHg and a respiratory rate was 20 breaths/min. She had some 
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signs of fluid overload such as jugular vein distension and lower extremity edema and was 
in functional New York Heart Association (NYHA) class III. Arterial blood gas analysis 
revealed hypoxemia (pH 7.41, PaCO2 35 mm Hg, PaO2 79 mmHg under O2 2L/min). The 
electrocardiogram revealed a sinus rhythm of 80 bpm, and right ventrichlar hypertrophy 
findings of the tall R waves in right precordial leads with right ventricular strain pattern (Fig. 1A). 
Chest x-ray (Fig. 1B) demonstrated bilateral hilar enlargement, a prominent medial arch 
and pulmonary artery trunk. Echocardiography confirmed dilatation of both the right atrium 
and right ventricle, and normal left ventricular function (left ventricular ejection fraction of 
62%) with flattening of ventricular septum (Fig 1C). Trans-mitral flow velocity pattern 
revealed abnormal relaxation, and the ratio of mitral inflow and mitral annular tissue 
Doppler imaging velocities (E/e') was within the normal range (8.3). Right heart 
catheterization demonstrated severe pulmonary hypertension (pulmonary arterial systolic 
pressure 94 mmHg, pulmonary arterial diastolic pressure 27 mmHg, mean pulmonary 
arterial pressure 48 mmHg) in contrast to the normal range of pulmonary capillary wedge 
pressure 14 mmHg. Other important parameters were cardiac output 3.9 L/min, (thermo 
dilution method) and pulmonary vascular resistance 540 dynes・s・cm-5. After these 
examinations, epoprostenol infusion therapy was introduced from the dose of 2μg/kg/min. 
However, pulmonary edema appeared and her oxygenation worsened dose dependent 
manner. Based on this clinical course, we made a diagnosis as PVOD clinically at the dose 
of epoprostenol was 12μg/kg/min. Thereafter, pulmonary edema gradually recovered in 
consistent with the reduction of the dose of epoprostenol infusion. A high-resolution 
computed tomography (HRCT) of her chest revealed centrilobular ground-glass opacities and 
septal thickness (Fig 1D). Lung transplantation was proposed as the sole treatment option to 
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prolong her life, but she declined. The patient died of renal failure and infection 4 months 
after the introduction of epoprostenol infusion therapy. Histopathological examination of her 
heart revealed hypertrophy of both ventricles without any apparent pathological interstitial 
fibrotic change (Fig 2A). In addition to the findings of small pulmonary arteries that revealed 
pronounced intimal fibrosis as typically seen in PAH (Fig 2B), small pulmonary vein also 
showed fibrotic occlusive lesions with marked intimal thickening characteristics of PVOD 
(Fig 2C). The capillaries in the alveolar area showed dilatation like angioma (Fig 2D) as well 
as the findings of intra-alveolar hemorrhage (Fig 2 E-G). On the basis of these pathological 
findings and clinic features, the patient was diagnosed as PVOD. 
 
Discussion 
Even though PAH and PVOD share many similarities, the clinical classification was 
modified to change to separate PVOD from other forms of PAH following the Fourth World 
Symposium on PAH held in 2008 at Dana Point, California [8]. It is currently well 
established that PAH associated with connective tissue disease such as systemic sclerosis 
is frequently less responsive or even refractory to pulmonary vasodilator therapies. The 
likely mechanism is a selective dilatation of the small pulmonary arteries without associated 
pulmonary venodilatation could cause an increase in trans-capillary hydrostatic pressure. 
Several papers have described the usefulness of HRCT to predict the presence of PVOD [9, 
10]. Our case also showed centrilobular ground-glass opacities and septal thickness; however, 
the findings of HRCT suggesting the presence of PVOD were obtained after the 
introduction of epoprostenol infusion therapy. Thus, we could not suspect PVOD until then. 
Several studies suggested that the frequencies of veno-occlusive types of disease in the 
6 
 
patients with PAH associated with connective tissue disease might be larger than expected, 
and there is some evidence from histopathological reports to support this hypothesis [5]. 
However, the current definite diagnosis of PVOD can be made by histopathologically, thus, 
limiting the estimation for the accurate involvements of this type of disease.  
In conclusion, we report a case with PVOD associated with systemic sclerosis which 
exhibits strong resistance to pulmonary vasodilator. We suggest that prevalence of 
veno-occlusive type of disease could be one of the major mechanisms of less responsive or 
even refractory to pulmonary vasodilator therapies to patients with pulmonary hypertension 
associated with connective tissue disease. 
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Figure 1: Imaging of the case 
Electrocardiogram at the admission revealed right ventrichlar hypertrophy findings of the tall 
R waves in right precordial leads with right ventricular strain pattern (A). Chest x-ray 
demonstrated bilateral hilar enlargement, a prominent medial arch and pulmonary artery 
trunk (B). Echocardiography revealed dilatation of right ventricle, and normal left ventricular 
function with flattening of ventricular septum (C). HRCT of her chest revealed centrilobular 
ground-glass opacities and septal thickness (D, arrow). 
 
Figure 2: Histopathological findings 
Macroscopic finding of heart; Transverse section of the heart showing hypertrophy of both 
the left and right ventricles (A). Small pulmonary artery revealed pronounced intimal fibrosis, 
as typically seen in PAH (B, Elastica van Gieson stain, ×200). Small pulmonary vein 
showed fibrotic occlusive lesions with marked intimal thickening characteristics of PVOD (C, 
Elastica van Gieson stain, ×200). The capillaries in the alveolar area showed dilatation like 
angioma (D, hematoxylin and eosin stain, ×200). Macroscopic findings of lung; alveolar 
hemorrhage was observed (E, arrow). Intra-alveolar macrophages were observed (F, arrow, 
hematoxylin and eosin stain, ×40). Fe-stain revealed the existence of iron in the alveoli (G, 
arrow, Fe-stain, ×200).  
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